
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
ORIGINAL RESEARCH article
Front. Cardiovasc. Med.
Sec. Heart Failure and Transplantation
Volume 12 - 2025 | doi: 10.3389/fcvm.2025.1499378
This article is part of the Research Topic A Patient-Centered Approach to the Management of Heart Failure and Comorbidities View all articles
The final, formatted version of the article will be published soon.
You have multiple emails registered with Frontiers:
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Myocardial infarction (MI) complicated by heart failure (HF) is a common and severe clinical condition associated with poor outcomes. Estimated plasma volume status (ePVS), a marker of congestion derived from hemoglobin and hematocrit, has shown promise in predicting outcomes in various cardiovascular diseases. This study aimed to investigate the relationship between ePVS and both short-term and long-term prognosis in patients with MI complicated by HF.Methods: A retrospective cohort study was conducted using data from the Medical Information Mart for Intensive Care IV (MIMIC-IV) database, including 3,238 patients with MI complicated by HF. Patients were stratified into quartiles based on ePVS values. The primary outcomes were in-hospital mortality, 180-day mortality, and 1-year mortality. Kaplan-Meier curves, multivariate Cox regression analysis, and subgroup analyses were performed to assess the relationship between ePVS and outcomes.Results: Kaplan-Meier analysis showed significant differences in survival rates across ePVS quartiles for all outcomes (P<0.001). Multivariate logistic regression analysis revealed that patients in the highest quartile of ePVS (Q4 vs Q1) had an independently increased risk of in-hospital mortality (OR 1.58, 95% CI 1.16-2.13, P=0.003). Cox regression analysis further demonstrated that higher ePVS (Q4 vs Q1) was associated with an increased risk of 180-day mortality (HR 1.45, 95% CI 1.19-1.75, P<0.001) and 1-year mortality (HR 1.51, 95% CI 1.27-1.80, P<0.001). Both Kaplan-Meier survival curves and restricted cubic spline models confirmed a positive association between ePVS and longterm mortality risks.The association between ePVS and long-term outcomes was stronger than for inhospital mortality. Subgroup analyses revealed that the relationship between ePVS and long-term mortality was more pronounced in patients with systolic blood pressure below 140 mmHg, lower LODS and OASIS scores, and those without hemorrhagic disorders or anemia (P for interaction <0.05).Conclusion: ePVS was an independent predictor of both short-term and long-term mortality in patients with MI complicated by HF. Its prognostic value was particularly significant for long-term outcomes, suggesting its potential utility in risk stratification and guiding treatment strategies for this high-risk population.
Keywords: Estimated plasma volume status, Myocardial Infarction, Heart Failure, prognosis, risk stratification
Received: 30 Sep 2024; Accepted: 17 Feb 2025.
Copyright: © 2025 Luo, Ma, Zhang, Jiang and Guo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Caixia Guo, Beijing Tongren Hospital, Capital Medical University, Beijing, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.